scholarly journals Anxiety and depression in adolescents with asthma and in their parents: a study in clinical practice

2019 ◽  
Vol 89 (3) ◽  
Author(s):  
Amelia Licari ◽  
Riccardo Ciprandi ◽  
Gianluigi Marseglia ◽  
Giorgio Ciprandi
Keyword(s):  
Clinical Practice ◽  
Allergic Asthma ◽  
Emotional Disorders ◽  
Psychological Assessment ◽  
Symptom Control ◽  
Real Life ◽  
Maternal Anxiety ◽  
Anxiety And Depression ◽  
Real Life Setting ◽  
Work Up

Emotional disorders, namely anxiety and depression, frequently affect adolescents with asthma. In addition, their parents also may present emotional problems. The objective of this study was to investigate anxiety and depression in asthmatic adolescents and in their parents in a real-life setting. A series of adolescents with allergic asthma were consecutively enrolled. Asthma was diagnosed according to the GINA document and consistently the symptom control grade was assessed. We used the HADS questionnaire for the adolescents, and HADS, STAY, and BDI questionnaires for their parents. Globally, 121 adolescents (71 males, 50 females, mean age 13.4±0.8 years, age ranging between 12 and 15 years) with allergic asthma and their parents were evaluated. Only 29% of adolescents had controlled asthma. Adolescents with controlled asthma had lower HADS-A and HADS-D scores than other patients, whereas there was no difference among parents. Severe maternal anxiety was more frequent in poorly controlled subjects than in partially controlled ones; absence of maternal anxiety was more common in controlled subjects. The preliminary results of the current study suggest that anxiety and depression are common in adolescents suffering from asthma as well as in their parents, mainly in mothers. Emotional disorders might affect also the asthma control. Thus, in clinical practice, the psychological assessment could be included in the asthma work-up.

scholarly journals A Multicenter, Prospective, Noninterventional Study in a Norwegian Cohort of Patients with Moderate-to-Severe Allergic Rhinitis Treated with MP-AzeFlu

2017 ◽  
Vol 8 (3) ◽  
pp. ar.2017.8.0216 ◽  
Author(s):  
Ralph Dollner ◽  
Petter Lorentz Larsen ◽  
Sinan Dheyauldeen ◽  
Sverre Steinsvåg
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Practice ◽  
Disease Control ◽  
Symptom Severity ◽  
Symptom Control ◽  
Real Life ◽  
Routine Clinical Practice ◽  
Vas Score ◽  
Receive Treatment ◽  
Noninterventional Study

Background Allergic Rhinitis and its Impact on Asthma guidelines recently recommended a treatment strategy for allergic rhinitis (AR) based on disease control rather than symptom severity by using a visual analog scale (VAS) to categorize control Objectives To evaluate the effectiveness of MP-AzeFlu (Dymista®) by using this VAS in routine clinical practice in Norway. MP-AzeFlu comprises a novel formulation that contains azelastine hydrochloride, fluticasone propionate and excipients delivered in a single spray. Methods This multicenter, prospective, noninterventional study enrolled patients (n = 160) with moderate-to-severe AR and acute symptoms who were eligible to receive treatment with MP-AzeFlu according to its summary of product characteristics. Patients assessed symptom severity by using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP-AzeFlu use on days 0, 1, 3, 7, and after ~14 days. On day 3, the patients assessed their level of disease control as well controlled, partly controlled, or uncontrolled. The proportion of Norwegian patients who achieved defined VAS score cutoffs for “well-controlled” and “partly controlled” AR were also calculated. Results MP-AzeFlu reduced the mean ± standard deviation VAS score from 68.1 ± 16.4 mm at baseline to 37.4 ± 25.9 mm on the last day, a reduction of 30.8 ± 27.2 mm. The results were consistent, irrespective of disease severity, phenotype (i.e., seasonal AR [SAR], perennial AR [PAR], SAR plus PAR, unknown) or age (i.e., 12–17, 18–65, and >65 years). Of the patients (with recorded data), 88.1% considered their symptoms to be partly or well controlled at day 3; and 19.5, 32.0, 50.0, and 61.0% of the patients achieved a ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7, and the last day, respectively. Conclusions MP-AzeFlu provided rapid sustained symptom control in a routine clinical practice in Norway, which provided support for its effectiveness for the treatment of AR in real life.

scholarly journals Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany

2009 ◽  
Vol 103 (11) ◽  
pp. 1725-1731 ◽  
Author(s):  
S. Korn ◽  
A. Thielen ◽  
S. Seyfried ◽  
C. Taube ◽  
O. Kornmann ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Real Life ◽  
Real Life Setting
Sign in / Sign up

Export Citation Format

Share Document